Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data
暂无分享,去创建一个
Morten Nielsen | Bjoern Peters | William H. Hildebrand | Birkir Reynisson | M. Nielsen | Bjoern Peters | W. Hildebrand | C. Barra | S. Kaabinejadian | Birkir Reynisson | Saghar Kaabinejadian | Carolina Barra
[1] O. Schilling,et al. Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. , 2011, Journal of proteome research.
[2] D. Neri,et al. Membranal and Blood‐Soluble HLA Class II Peptidome Analyses Using Data‐Dependent and Independent Acquisition , 2018, Proteomics.
[3] Jennifer G. Abelin,et al. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. , 2019, Immunity.
[4] Massimo Andreatta,et al. NNAlign_MA; MHC Peptidome Deconvolution for Accurate MHC Binding Motif Characterization and Improved T-cell Epitope Predictions* , 2019, Molecular & Cellular Proteomics.
[5] Morten Nielsen,et al. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions , 2011, Immunogenetics.
[6] William S. Lane,et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.
[7] Valerio Zolla,et al. The Dendritic Cell Major Histocompatibility Complex II (MHC II) Peptidome Derives from a Variety of Processing Pathways and Includes Peptides with a Broad Spectrum of HLA-DM Sensitivity* , 2016, The Journal of Biological Chemistry.
[8] J. Traherne,et al. Human MHC architecture and evolution: implications for disease association studies , 2008, International journal of immunogenetics.
[9] David Gfeller,et al. Predicting Antigen Presentation—What Could We Learn From a Million Peptides? , 2018, Front. Immunol..
[10] Morten Nielsen,et al. Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion , 2012, Nucleic Acids Res..
[11] A Sette,et al. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides , 1987, Science.
[12] Maria V. Tejada-Simon,et al. Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions1 , 2001, The Journal of Immunology.
[13] Etienne Caron,et al. Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry* , 2015, Molecular & Cellular Proteomics.
[14] Oliver Kohlbacher,et al. HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy , 2017, Oncoimmunology.
[15] Morten Nielsen,et al. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method , 2007, BMC Bioinformatics.
[16] M. Nielsen,et al. NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data , 2017, The Journal of Immunology.
[17] C. Bailey-Kellogg,et al. Design and engineering of deimmunized biotherapeutics. , 2016, Current opinion in structural biology.
[18] Hau-San Wong,et al. TEPITOPEpan: Extending TEPITOPE for Peptide Binding Prediction Covering over 700 HLA-DR Molecules , 2012, PloS one.
[19] S. Shaffer,et al. HLA-DO Modulates the Diversity of the MHC-II Self-peptidome* , 2018, Molecular & Cellular Proteomics.
[20] Shabaz Mohammed,et al. Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity* , 2016, Molecular & Cellular Proteomics.
[21] O. Lund,et al. NetMHCpan, a method for MHC class I binding prediction beyond humans , 2008, Immunogenetics.
[22] Sri H. Ramarathinam,et al. A Systems Approach to Understand Antigen Presentation and the Immune Response. , 2016, Methods in molecular biology.
[23] Morten Nielsen,et al. MHC Class II epitope predictive algorithms , 2010, Immunology.
[24] Andreas Handel,et al. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells , 2017, Nature.
[25] S. Ribeiro,et al. CD4+ T Cell Epitope Discovery and Rational Vaccine Design , 2010, Archivum Immunologiae et Therapiae Experimentalis.
[26] O. Lund,et al. novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .
[27] Dario Neri,et al. High‐resolution analysis of the murine MHC class II immunopeptidome , 2016, European journal of immunology.
[28] C. Freund,et al. Quantification of HLA-DM-Dependent Major Histocompatibility Complex of Class II Immunopeptidomes by the Peptide Landscape Antigenic Epitope Alignment Utility , 2018, Front. Immunol..
[29] Jennifer G. Abelin,et al. Mass Spectrometry Profiling of HLA‐Associated Peptidomes in Mono‐allelic Cells Enables More Accurate Epitope Prediction , 2017, Immunity.
[30] Morten Nielsen,et al. Improved peptide-MHC class II interaction prediction through integration of eluted ligand and peptide affinity data , 2019, Immunogenetics.
[31] Morten Nielsen,et al. GibbsCluster: unsupervised clustering and alignment of peptide sequences , 2017, Nucleic Acids Res..
[32] Morten Nielsen,et al. Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification , 2015, Immunogenetics.
[33] Morten Nielsen,et al. NNAlign: a platform to construct and evaluate artificial neural network models of receptor–ligand interactions , 2017, Nucleic Acids Res..
[34] Morten Nielsen,et al. Footprints of antigen processing boost MHC class II natural ligand predictions , 2018, Genome Medicine.
[35] David Gfeller,et al. Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide–HLA Interactions , 2016, The Journal of Immunology.
[36] Catherine E Costello,et al. Immunogenic HLA-DR-Presented Self-Peptides Identified Directly from Clinical Samples of Synovial Tissue, Synovial Fluid, or Peripheral Blood in Patients with Rheumatoid Arthritis or Lyme Arthritis. , 2017, Journal of proteome research.
[37] M. Nielsen,et al. Machine learning reveals a non‐canonical mode of peptide binding to MHC class II molecules , 2017, Immunology.
[38] O. Lund,et al. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ , 2013, Immunogenetics.
[39] Russ B. Altman,et al. Predicting HLA class II antigen presentation through integrated deep learning , 2019, Nature Biotechnology.
[40] Ash A. Alizadeh,et al. Antigen Presentation Profiling Reveals Recognition of Lymphoma Immunoglobulin Neoantigens , 2017, Nature.
[41] Sri H. Ramarathinam,et al. The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis , 2018, The Journal of Biological Chemistry.
[42] Gajendra P. S. Raghava,et al. ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..
[43] Anders Eklund,et al. Approach for Identifying Human Leukocyte Antigen (HLA)-DR Bound Peptides from Scarce Clinical Samples * , 2016, Molecular & Cellular Proteomics.
[44] S. Shaffer,et al. HLA-DO Modulates the Diversity of the MHC-II Self-peptidome. , 2019, Molecular & cellular proteomics : MCP.
[45] E. Unanue,et al. Variations in MHC Class II Antigen Processing and Presentation in Health and Disease. , 2016, Annual review of immunology.
[46] Morten Nielsen,et al. Improved Prediction of Bovine Leucocyte Antigens (BoLA) Presented Ligands by Use of Mass-Spectrometry-Determined Ligand and in Vitro Binding Data , 2017, Journal of proteome research.
[47] George Coukos,et al. Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes , 2019, Nature Biotechnology.
[48] Sandeep Kumar Dhanda,et al. Determination of a Predictive Cleavage Motif for Eluted Major Histocompatibility Complex Class II Ligands , 2018, Front. Immunol..
[49] M. Mann,et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry , 2016, Nature Communications.
[50] Francesco Leonetti,et al. Substrate Profiling of Cysteine Proteases Using a Combinatorial Peptide Library Identifies Functionally Unique Specificities* , 2006, Journal of Biological Chemistry.
[51] Alessandro Sette,et al. The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..
[52] R. Toes,et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis , 2013, The Journal of experimental medicine.
[53] Morten Nielsen,et al. Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan , 2008, PLoS Comput. Biol..
[54] O. Lund,et al. NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence , 2007, PloS one.
[55] Morten Nielsen,et al. Computational Tools for the Identification and Interpretation of Sequence Motifs in Immunopeptidomes , 2018, Proteomics.
[56] Hong Yu,et al. Identification of MHC-Bound Peptides from Dendritic Cells Infected with Salmonella enterica Strain SL1344: Implications for a Nontyphoidal Salmonella Vaccine. , 2017, Journal of proteome research.
[57] Morten Nielsen,et al. Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires , 2014, Immunogenetics.
[58] S. Mallal,et al. Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses , 2019, Front. Immunol..
[59] Frank Noé,et al. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation , 2017, Front. Immunol..
[60] J. Greenbaum,et al. Improved methods for predicting peptide binding affinity to MHC class II molecules , 2018, Immunology.
[61] V. Velculescu,et al. High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets , 2019, Cancer Immunology Research.
[62] Oliver Kohlbacher,et al. Immunoinformatics and epitope prediction in the age of genomic medicine , 2015, Genome Medicine.
[63] U. Şahin,et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.
[64] O. Lund,et al. Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy? , 2012, Expert review of vaccines.
[65] J. Voorberg,et al. Analysis of the HLA‐DR peptidome from human dendritic cells reveals high affinity repertoires and nonconventional pathways of peptide generation , 2017, Journal of leukocyte biology.
[66] The UniProt Consortium,et al. UniProt: a worldwide hub of protein knowledge , 2018, Nucleic Acids Res..
[67] Morten Nielsen,et al. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction , 2009, BMC Bioinformatics.